日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer

REACTiVe-2:转移性胰腺癌患者接受 (m)FOLFIRINOX 方案治疗后,树突状细胞疫苗接种和激动性 CD40 疗法的 I 期评估

Songul Kucukcelebi # ,Freek R van 't Land # ,Sjoerd H van der Burg ,Ferry A L M Eskens ,Marjolein Y V Homs ,Marcella Willemsen ,Anne Onrust-van Schoonhoven ,Nina E M Rozendaal ,Amine Fellah ,Disha Vadgama ,Miranda Moskie ,Koen Bezemer ,Michail Doukas ,Casper W F van Eijck ,Ralph Stadhouders ,Judith de Vos-Geelen ,Aniek E van Diepen ,Ilona Enninga ,Rob Meijer ,Sumeet V Ambarkhane ,Peter Ellmark ,Joachim G J V Aerts ,Christianne Groeneveldt ,Casper H J van Eijck

CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1

CD40激动剂mitazalimab联合mFOLFIRINOX方案治疗未经治疗的转移性胰腺癌:OPTIMIZE-1研究中与疗效相关的生物标志物

Jean-Luc Van Laethem ,Karen Geboes ,Ivan Borbath ,Teresa Macarulla Mercade ,Aurélien Lambert ,Philippe Cassier ,Hans Prenen ,Emmanuel Mitry ,Jean-Frédéric Blanc ,Lorenzo Pilla ,Jaime Feliu ,Mercedes Rodriguez Garrote ,Roberto Antonio Pazo-Cid ,Inmaculada Gallego ,Karin Enell Smith ,Karin Nordbladh ,David Gomez Jimenez ,Peter Ellmark ,Yago Pico de Coaña ,Sumeet Vijay Ambarkhane ,Gregory L Beatty ,Eileen M O'Reilly

ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell-Dependent Tumor Immunity and Synergizes with PD-1 Blockade

ATOR-4066 是一种靶向 CD40 和 CEACAM5 的双特异性抗体,可诱导强烈的髓系和 T 细胞依赖性肿瘤免疫,并与 PD-1 阻断剂产生协同作用。

Hampus Andersson ,Ida Uddbäck ,Tova Hermodsson ,Mona Celander ,Amulya Krishna Shetty ,Lill Ljung ,Anneli Nilsson ,Anette Sundstedt ,Laura von Schantz ,Laura A Varas ,Mattias Levin ,Anna Säll ,Dietmar Weilguny ,Kim Jansson ,Sara Fritzell ,Karin Hägerbrand ,Malin Lindstedt # ,Peter Ellmark #

ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1

ATOR-1017 (evunzekibart) 是一种 Fc-γ 受体条件性 4-1BB 激动剂,旨在实现最佳安全性和有效性,与抗 PD-1 联合使用可激活耗竭的 T 细胞

Karin Enell Smith #, Sara Fritzell #, Anneli Nilsson, Karin Barchan, Anna Rosén, Lena Schultz, Laura Varas, Anna Säll, Nadia Rose, Maria Håkansson, Laura von Schantz, Peter Ellmark

Transcriptional profiling demonstrates altered characteristics of CD8+ cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia

转录组分析表明,TP53突变型急性髓系白血病中CD8+细胞毒性T细胞和调节性T细胞的特征发生了改变。

Milad Abolhalaj ,Viktor Sincic ,Henrik Lilljebjörn ,Carl Sandén ,Alar Aab ,Karin Hägerbrand ,Peter Ellmark ,Carl A K Borrebaeck ,Thoas Fioretos ,Kristina Lundberg

CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation

CD137 (4-1BB) 对 CD8+ T 细胞的共刺激作用,在顺式而非反式条件下对 CD3-TCR 刺激更为有效。

Itziar Otano # ,Arantza Azpilikueta # ,Javier Glez-Vaz ,Maite Alvarez ,José Medina-Echeverz ,Ivan Cortés-Domínguez ,Carlos Ortiz-de-Solorzano ,Peter Ellmark ,Sara Fritzell ,Gabriela Hernandez-Hoyos ,Michelle Hase Nelson ,María Carmen Ochoa ,Elixabet Bolaños ,Doina Cuculescu ,Patricia Jaúregui ,Sandra Sanchez-Gregorio ,Iñaki Etxeberria ,María E Rodriguez-Ruiz ,Miguel F Sanmamed ,Álvaro Teijeira ,Pedro Berraondo ,Ignacio Melero

The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo

人类抗 CD40 激动剂抗体米塔扎利单抗 (ADC-1013; JNJ-64457107) 可激活抗原呈递细胞、促进抗原特异性 T 细胞扩增并增强模型癌症疫苗在体内的抗肿瘤功效

Adnan Deronic, Anneli Nilsson, Mia Thagesson, Doreen Werchau, Karin Enell Smith, Peter Ellmark

Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy

肿瘤内皮细胞上调 IDO1 是一种免疫抑制反馈机制,可降低对 CD40 刺激免疫疗法的反应

Maria Georganaki, Mohanraj Ramachandran, Sander Tuit, Nicolás Gonzalo Núñez, Alexandros Karampatzakis, Grammatiki Fotaki, Luuk van Hooren, Hua Huang, Roberta Lugano, Thomas Ulas, Aura Kaunisto, Eric C Holland, Peter Ellmark, Sara M Mangsbo, Joachim Schultze, Magnus Essand, Sonia Tugues, Anna Dimberg

Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression

将低剂量的抗 CTLA4、抗 CD137 和抗 OX40 组合注射到小鼠肿瘤中或肿瘤引流淋巴结近端可诱导全身肿瘤消退

Jonathan P O Hebb, Adriane R Mosley, Felipe Vences-Catalán, Narendiran Rajasekaran, Anna Rosén, Peter Ellmark, Dean W Felsher

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo

局部 CTLA4 阻断可有效抑制实验性胰腺腺癌体内生长

Linda C Sandin, Fredrik Eriksson, Peter Ellmark, Angelica Si Loskog, Thomas H Tötterman, Sara M Mangsbo